9 results on '"Jackie Perry"'
Search Results
2. Identification of genomic changes associated with cisplatin resistance in testicular germ cell tumor cell lines
- Author
-
Xueying Mao, Tracy Chaplin, R. Tim D. Oliver, Bryan D. Young, Yong-Jie Lu, Simon P. Joel, Jean-Baptiste Cazier, Jackie Perry, and Elodie E. Noel
- Subjects
Male ,Cancer Research ,medicine.medical_treatment ,Testicular Germ Cell Tumor ,Gene Dosage ,Single-nucleotide polymorphism ,Antineoplastic Agents ,Drug resistance ,Biology ,Gene dosage ,Polymorphism, Single Nucleotide ,Testicular Neoplasms ,Genetics ,medicine ,Tumor Cells, Cultured ,Humans ,In Situ Hybridization, Fluorescence ,Cisplatin ,Chromosome Aberrations ,Chemotherapy ,medicine.diagnostic_test ,Microarray analysis techniques ,Microarray Analysis ,Molecular biology ,Drug Resistance, Neoplasm ,Fluorescence in situ hybridization ,medicine.drug - Abstract
Since the introduction of cisplatin into the clinic, the treatment of patients with a variety of solid tumors including testicular germ cell tumors, ovarian and lung cancers, has dramatically improved. One of the main causes for therapeutic failure in these malignancies is the development of drug resistance. Testicular germ cell tumors (TGCTs), the most common malignancy in young men, exhibit extreme sensitivity to cisplatin-based chemotherapy, making them an ideal model for investigating the mechanisms of cisplatin chemo-sensitivity and resistance. TGCT development and pathogenesis have been well studied but little is known about the genetic background in chemo-resistant cases. We investigated genomic differences between three TGCT parental cell lines and their cisplatin resistant derivatives. Using 10K single nucleotide polymorphism (SNP) microarray analysis, we identified two small chromosomal regions with consistent copy number changes across all three pairs of resistant cell lines. These were an 8.7 Mb region at 6q26-27, which displayed consistent copy number gain and a 0.3 Mb deletion involving 4 SNPs at 10p14. Both the chromosomal gain and loss were confirmed by fluorescence in situ hybridization. The significance of these regions should be further investigated as they may contain key genes involved in the development of chemo- resistance to cisplatin-based treatment in TGCTs and other cancers. © 2008 Wiley-Liss, Inc.
- Published
- 2016
- Full Text
- View/download PDF
3. Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients With Fluorouracil-Refractory Metastatic Colon Cancer
- Author
-
John D. Chester, Jackie Perry, Simon P. Joel, Christopher J. Button, Susan L. Cheeseman, Matthew T. Seymour, Theresa Davis, Geoffrey D. Hall, and Michael Braun
- Subjects
Adult ,Male ,Antimetabolites, Antineoplastic ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Administration, Oral ,Pharmacology ,Neutropenia ,Irinotecan ,Gastroenterology ,Pharmacokinetics ,Oral administration ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Infusions, Intravenous ,Aged ,Neoplasm Staging ,Chemotherapy ,business.industry ,Area under the curve ,Middle Aged ,Ciclosporin ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Treatment Outcome ,Oncology ,Drug Resistance, Neoplasm ,Fluorouracil ,Colonic Neoplasms ,Cyclosporine ,Camptothecin ,Female ,business ,medicine.drug - Abstract
Purpose: To assess the safety and toxicity profile of escalating doses of intravenous irinotecan, in combination with a fixed dose of oral ciclosporin (Cs) and to determine the pharmacokinetic profile of irinotecan and its metabolites. Patients and Methods: Patients with fluorouracil-refractory metastatic colorectal cancer received escalating doses of intravenous irinotecan from 40 to 125 mg/m2 every 2 weeks in combination with a fixed dose of oral Cs (5 mg/kg bid for 3 days). Pharmacokinetic analysis of plasma irinotecan and its metabolites SN38 and SN38G was performed during paired cycles with and without Cs. Results: Thirty-seven patients were treated. Dose-limiting toxicity of grade 4 neutropenia was seen at an irinotecan dose of 125 mg/m2. There was no grade 4 diarrhea, and only one patient experienced grade 3 diarrhea. Toxicities caused by Cs were generally mild. Pharmacokinetic studies demonstrated that irinotecan clearance was reduced from 13.4 to 5.8 L/h/m2 and area under the curve (AUC)0-tn was increased 2.2-fold by the coadministration of Cs. Similar significant increases in AUC0-24h were seen for both SN38 and SN38G (2.2-fold and 2.3-fold, respectively) in the presence of Cs. Antitumor activity was seen at every irinotecan dose level. Conclusion: The maximum tolerated irinotecan dose and recommended dose for phase II studies is 100 mg/m2 every 2 weeks. Dose-limiting diarrhea was not seen during this study, supporting the hypothesis that pharmacokinetic modulation of irinotecan by Cs may improve its therapeutic index. Further studies using this combination are warranted.
- Published
- 2003
- Full Text
- View/download PDF
4. A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP
- Author
-
Christiana Kitromilidou, Eva H. McGrowder, Thomas Powles, Essam Ghazaly, Jackie Perry, and Simon P. Joel
- Subjects
Cancer Research ,Indazoles ,medicine.drug_class ,Intracellular Space ,Antineoplastic Agents ,Pharmacology ,Lapatinib ,Tyrosine-kinase inhibitor ,Flow cytometry ,Cell Line, Tumor ,medicine ,ATP Binding Cassette Transporter, Subfamily G, Member 2 ,Humans ,Viability assay ,skin and connective tissue diseases ,Protein Kinase Inhibitors ,Chromatography, High Pressure Liquid ,Cisplatin ,Sulfonamides ,medicine.diagnostic_test ,Chemistry ,Cell growth ,Cell Cycle ,Drug Synergism ,Flow Cytometry ,Neoplasm Proteins ,Pyrimidines ,Oncology ,Quinazolines ,ATP-Binding Cassette Transporters ,Efflux ,Drug Screening Assays, Antitumor ,Intracellular ,medicine.drug - Abstract
Lapatinib is a specific HER1 and 2 targeted tyrosine kinase inhibitor now widely used in combination with chemotherapy in the clinical setting. In this work, we investigated the interactions between lapatinib and specific chemotherapy agents (cisplatin, SN-38, topotecan) in a panel of cell lines [breast (n = 2), lung (n = 2), testis (n = 4)]. A high-sensitivity cell proliferation/cytotoxicity ATP assay and flow cytometry were used to determine cell viability, apoptosis, and the effect of the drugs on cell-cycle distribution. CalcuSyn analysis was employed to formally identify synergistic interactions between drugs. Intracellular concentrations of SN-38 were measured using a novel high-performance liquid chromatography (HPLC) technique. Flow cytometry and HPLC techniques were used to identify the effect of lapatinib on drug influx and efflux pumps, using specific substrates and inhibitors of these pumps. Results showed significant synergy between SN-38, and lapatinib in the majority of cell lines (combination index < 0.75), associated with increased apoptosis. This synergy was not universal but, when observed (Susa S/R, H1975, H358, and MDA-MB-231 cell lines), was related to SN-38 intracellular accumulation (2.2- to 4.8-fold increase, P < 0.05 for each), attributable to the inhibition of the breast cancer–related protein (BCRP) efflux pump by lapatinib. Flow cytometry analysis showed that lapatinib (10 μmol/L) inhibited the efflux of mitoxantrone, a specific substrate of the BCRP pump, in a manner similar to fumitremorgin C, a known BCRP inhibitor, confirming lapatinib as a BCRP inhibitor. This work shows that lapatinib has a direct inhibitory effect on BCRP accounting for the synergistic findings. The synergy is cell line dependent and related to the activity of specific efflux pumps. Mol Cancer Ther; 9(12); 3322–9. ©2010 AACR.
- Published
- 2010
5. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers
- Author
-
Simon P. Joel, Swee Y. Sharp, Sakunthala C. Kudahetti, Bryan D. Young, Jackie Perry, Thomas Powles, Tracy Chaplin, R. Tim D. Oliver, Marc Yeste-Velasco, Janet Shipley, Alan McIntyre, Yong-Jie Lu, Liyan Xue, Ningfeng F. Li, Xueying Mao, Ling Shan, Elodie E. Noel, and Daniel M. Berney
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Cell Survival ,Testicular Germ Cell Tumor ,Antineoplastic Agents ,Biology ,Pathology and Forensic Medicine ,Prostate cancer ,Testicular Neoplasms ,Cell Line, Tumor ,Gene expression ,medicine ,Humans ,Cyclin D1 ,RNA, Small Interfering ,Cell Proliferation ,Cisplatin ,Ovarian Neoplasms ,Gene knockdown ,Comparative Genomic Hybridization ,Cell growth ,Microarray analysis techniques ,Gene Expression Profiling ,Cancer ,Prostatic Neoplasms ,Neoplasms, Germ Cell and Embryonal ,medicine.disease ,Microarray Analysis ,Drug Resistance, Neoplasm ,Cancer research ,Female ,medicine.drug ,Regular Articles - Abstract
Development of chemoresistance limits the clinical efficiency of platinum-based therapy. Although many resistance mechanisms have been demonstrated, genetic/molecular alterations responsible for drug resistance in the majority of clinical cases have not been identified. We analyzed three pairs of testicular germ cell tumor cell lines using Affymetrix expression microarrays and revealed a limited number of differentially expressed genes across the cell lines when comparing the parental and resistant cells. Among them, CCND1 was the most significantly differentially expressed gene. Analysis of testicular germ cell tumor clinical samples by quantitative reverse transcription PCR analysis revealed that overall expression of CCND1 was significantly higher in resistant cases compared with sensitive samples (P < 0.0001). We also found that CCND1 was dramatically overexpressed both in induced and intrinsically resistant samples of ovarian and prostate cancer. Finally combined CCND1 knockdown using small-interfering RNA and cisplatin treatment inhibited cell growth in vitro significantly more effectively than any of these single treatments. Therefore, deregulation of CCND1 may be a major cause of cisplatin resistance in testicular germ cell tumors and may also be implicated in ovarian and prostate cancers. CCND1 could be potentially used as a marker for treatment stratification and as a molecular target to improve the treatment of platinum-resistant tumors.
- Published
- 2010
6. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines
- Author
-
Jonathan Shamash, Eva H. McGrowder, Thomas Powles, Tim Oliver, Jackie Perry, Yong-Jie Lu, Simon P. Joel, Elodie E. Noel, and Arthi Veerupillai
- Subjects
Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Organoplatinum Compounds ,Cell Survival ,medicine.medical_treatment ,Blotting, Western ,Antineoplastic Agents ,Apoptosis ,Satraplatin ,Drug resistance ,Biology ,Oncogene Protein p21(ras) ,Toxicology ,Flow cytometry ,chemistry.chemical_compound ,Testicular Neoplasms ,Cell Line, Tumor ,medicine ,Neoplasm ,Humans ,Pharmacology (medical) ,Pharmacology ,Cisplatin ,Chemotherapy ,medicine.diagnostic_test ,Cell Cycle ,Proto-Oncogene Proteins c-mdm2 ,DNA, Neoplasm ,Cell cycle ,Neoplasms, Germ Cell and Embryonal ,medicine.disease ,Flow Cytometry ,Oxaliplatin ,Gene Expression Regulation, Neoplastic ,Oncology ,chemistry ,Drug Resistance, Neoplasm ,Cancer research ,Tumor Suppressor Protein p53 ,medicine.drug - Abstract
Germ cell tumours (GCT) can become resistant to cisplatin, which is associated with a relatively poor prognosis. Oxaliplatin and satraplatin have been developed to overcome cisplatin resistance in other cancers, but their effect in cisplatin resistant (cisR) GCTs is unclear. In this work we address this issue by comparing their efficacy in three paired sensitive and cisR GCT cell lines.Three established cisplatin sensitive (cisS) and resistant cell line pairs were used (GCT27, GCT27r: SUSA, SUSAr: 833k, 833kr). Viability was assessed using a luciferase based ATP assay and EC(50) and EC(80) concentrations were calculated. Western blot analysis and flow cytometry was used for further assessment.Sensitivity to the three platinum compounds was broadly similar in the three cisS lines GCT cell lines (EC(50) = 0.27-0.51 microM for cisplatin, 0.52-0.79 microM for oxaliplatin, 0.31-1.26 microM for satraplatin). EC(50) values for cisplatin in the three cisR sub lines were 1.8- to 3.8-fold higher than in the sensitive parental lines. Cross resistance to satraplatin and oxaliplatin occurred in all three cisR cell lines (resistance factor 1.9-4.4), with the exception of oxaliplatin in the 833Kr (resistance factor 0.9). Differences in the effect of specific drugs on cell cycle distribution, p53, p21 and MDM2 were observed.These data suggest that satraplatin and oxaliplatin could theoretically be used in chemo-naive GCTs and support the further clinical evaluation of these agents in this setting. The mechanism of cross resistance to these drugs appears multifactorial.
- Published
- 2008
7. Abstract 3256: Sphingolipid regulation by sphingosine kinase anchoring protein (SKAP) and its implication in cancer
- Author
-
Essam Ghazaly, Bryan D. Young, Adedayo Oke, Paul Smith, Zeinab Al-Shareef, Jackie Perry, and Simon P. Joel
- Subjects
Cancer Research ,Ceramide ,Sphingosine ,Sphingosine kinase ,Transfection ,Biology ,Molecular biology ,chemistry.chemical_compound ,Oncology ,chemistry ,Cell culture ,Cancer cell ,lipids (amino acids, peptides, and proteins) ,Sphingosine-1-phosphate ,Protein kinase C - Abstract
Background: Sphingolipids are important in cancer cell signalling. Sphingosine 1 phosphate (S1P) promotes cell survival and resistance to apoptosis, while S1P precursors ceramide (CER) and sphingosine (SPH), mediate antiproliferative and apoptotic responses. S1P is generated from SPH by sphingosine kinase (SK) enzymes (SK1 and SK2), with SK activity and localisation regulated by other proteins, including PKC, PKA and a SK anchoring protein (SKAP) that has been reported to negatively regulate SK1 activity in fibroblasts. S1P localisation is thought to play an important role in its function. Based on our preliminary observation in primary AML cells that SKAP expression resulted in an increase in S1P, we have investigated the effect of SKAP transfection on S1P production and localisation. Methods: K562, (and for some confirmatory experiments MCF-7), cells were transfected with the SKAP gene using standard techniques. SKAP is normally silenced in both cell lines. Transfection was confirmed by RNA expression. Intracellular and extracellular S1P and SPH, and intracellular SK activity (based on the production of C17 S1P from C17 SPH, an unnatural SPH that is a SK substrate) in intact cells were measured by LC-MS/MS. Phorbol 12-myristate 13-acetate (PMA) was used to induce membrane associated SK function, and MK-571 and fumitremorgen C (FTC) were used to block S1P efflux through ABCC1 and ABCG2 efflux pumps, respectively. Chemosensitivity to doxorubicin and imatinib in transfected cells was also studied. Results: K562 cells transfected with the SKAP gene showed a 2.5 fold increase in intracellular and extracellular levels of basal S1P compared to vector alone control. (In MCF-7 cells SKAP transfection resulted in an almost 10-fold increase in S1P). Further studies in K562 cells confirmed a significant increase in intracellular SK activity in SKAP transfected compared to vector alone cells, based on C17 S1P production (8.8 ± 2.6 vs 1.4 ± 0.4 ng/106 cells respectively after 24 hrs, p< 0.05). This increase was also observed, though to a lesser extent, in extracellular C17 S1P (678 ± 50 in SKAP vs 462 ± 47 pg/ml in vector alone, p< 0.05). In a proliferation assay this increase in SK activity was associated with a 25% increase in viable cell number (p Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3256. doi:1538-7445.AM2012-3256
- Published
- 2012
- Full Text
- View/download PDF
8. CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other human cancers
- Author
-
Marc Yeste-Velasco, Simon P. Joel, Janet Shipley, Sakunthala C. Kudahetti, Yong-Jie Lu, Bryan D. Young, R. Tim D. Oliver, Jackie Perry, Ningfeng F. Li, Xueying Mao, Elodie E. Noel, Daniel M. Berney, and Tracy Chaplin
- Subjects
Cancer Research ,Cyclin D1 ,Cisplatin resistance ,Genetics ,Cancer research ,Biology ,Molecular Biology ,Testicular germ cell - Published
- 2010
- Full Text
- View/download PDF
9. A synergistic interaction between lapatinib and topoisomerase I inhibitors in cisplatin sensitive and resistant cancer cell lines
- Author
-
Thomas Powles, Jonathan Shamash, Jackie Perry, E. Nsubuga, Simon P. Joel, and Iman El-Hariry
- Subjects
Cisplatin ,Cancer Research ,business.industry ,medicine.drug_class ,Topoisomerase-I Inhibitor ,Lapatinib ,Tyrosine-kinase inhibitor ,respiratory tract diseases ,body regions ,Oncology ,Cell culture ,Resistant cancer ,embryonic structures ,Cancer research ,Medicine ,skin and connective tissue diseases ,business ,medicine.drug - Abstract
14618 Background: Lapatinib is a HER1 and 2 tyrosine kinase inhibitor (TKI). Little is know about its interaction with other chemotherpy drugs. In this work investigate interactions between lapatin...
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.